Tag: BaxHTN
Phase III trials show Baxdrostat lowers systolic BP in resistant hypertension
In the Phase III BaxHTN study, baxdrostat 2 mg achieved a placebo-adjusted reduction in seated systolic blood pressure of 9.8 mmHg at 12 weeks, meeting the primary endpoint